China’s Health Ministries (Pt. 3): Who Controls the Money – and Why the NHSA Matters Most
An essential guide to the National Healthcare Security Administration - the gatekeeper of market access, at the hardest edge of China’s health system.
🔬Welcome to Part 3 of my deep dive series into China’s key health ministries.
Part 1 covered China’s core Ministry of Health, the National Health Commission, Part 2 covered the drug regulators at the centre of Chinas biotech rise, the National Medical Products Administration, and my foundational explainer “Who Actually Runs Health in China?” mapped out the main stakeholders of health policy and power.
Winter in China is NRDL season.
For anyone working in China’s life sciences sector, it marks the most consequential period of the year. As the National Healthcare Security Administration releases China’s annual National Reimbursement Drug List, the biopharma industry collectively holds its breath.
Treatments need to be on this list to reach patients at scale in China. List inclusion allows drugs to be reimbursed through the public health insurance system, which today covers roughly 95–98% of the population. Getting listed is therefore essential to accessing the majority of China’s patients - but it comes at a steep cost. Savage price cuts averaging 60–90% are common.
Failing to list, meanwhile, means that most patients who want the drug will not be able to afford out-of-pocket costs, effectively shutting companies out of most of China’s otherwise immense patient market. As both a gateway to mass access and a source of relentless price pressure, the system forces biopharma companies to design their entire China strategy around anticipated price cuts and to make volume economics work on razor-thin margins - what is referred to as volume-based procurement (VBP).
This is why, from late summer onwards, anxiety begins brewing across the sector. Large and small companies alike, and foreign and domestic both, all start to reorganise themselves around this singular drive. Scenarios are modelled and remodelled. Prices are cut on spreadsheets, restored and cut again. Internal decks circulate. Board conversations are rehearsed across global and China teams.
When companies enter reimbursement negotiations, they arrive with internal “walk-away” prices based on what they are willing to give up, and what they cannot survive losing. And yet, despite all of that preparation, they cannot control the outcome.
The NHSA’s deliberations are not public, and the rationales of its judging panels are not published in detail. It’s not certain whether a drug will make the list. It’s not known how a final price will compare with competitors until after it becomes public. And there is no appeal process that resembles the transparency of Western drug pricing mechanisms. That is why the entire process still feels like a black box, particularly to players who are new to China, and fresh to this brutal game.
So when the public announcement comes (usually late December to mid-January), it arrives as a definitive, binary answer. If your drug does not enter China’s public health insurance system, you regroup and try again next year. If it does, the celebration is still often muted, because the next step is immediately unforgiving: sell enough volume to make enough returns, in order to survive.
This annual theatre of power and influence is concentrated within a single institution: China’s NHSA may be the most powerful health ministry of them all, because it decides what the system will pay for, at what price and on whose terms. I’ve already written about how the National Health Commission sets strategic direction and reform priorities, and how the National Medical Products Administration decides which products are safe and effective. But though policy can suggest, and regulation can approve, money ultimately disciplines behaviour.
And so, to understand how the entire health system behaves, we need to look at its hardest edge. This post focuses on the institution of the NHSA itself: how it came to wield this power, how it operates and where its limits lie. When the 2026 National Reimbursement Drug List is released, I will return to analyse what changed, who gained access, who absorbed the cost and what it reveals about the direction of China’s health reforms in practice.
NHSA 101
Founded only in 2018, the National Healthcare Security Administration is one of China’s youngest ministries.
Its Chinese name 国家医疗保障局 is revealing. 医疗 yiliao refers to medical / healthcare, and 保障 baozhang refers to security, protection or guarantee, drawn from the same linguistic family as social security, pensions and employment protections. In everyday shorthand, the NHSA is simply referred to as 医保局, medical security. The emphasis is on protection as a system function rather than insurance itself as a product. The agency’s mandate is less about optimising individual coverage decisions, and more about ensuring that China’s healthcare can remain financially sustainable and socially reliable.
